Paperonium

Alzheimer’s research · Neurology · 2026

Summary: 73.5% of Alzheimer drug trials used lab tests or brain scans. Same paper’s results: 56.3%.

Used lab test or brain scan56.3%Its own results: 134 of 238The summary73.5%Symptom test as main measurethe summary used this row175 of 23855%60657075
Used lab test or brain scan56.3%Its own results: 134 of 238The summary73.5%Symptom test as main measurethe summary used this row175 of 23855%60657075

Share of the 238 Alzheimer drug trials using each kind of measure

The paper says

A paper that reviewed 238 Alzheimer drug trials says in its summary (the overview at the top) that 175 of them (73.5%) used at least one lab test or brain scan to check whether the drug worked, not only symptom tests such as memory quizzes.

Its own data show

The detailed results further down count the same thing and get 134 of 238 (56.3%). The paper’s separate counts for trials at earlier and later stages of testing also add up to 134 (79 + 55). The summary’s 175 is exactly another line of those results: trials using a symptom test as a main measure.

A trial’s main measures are the one or few results chosen to decide whether the drug worked; it can track other tests on the side. Many readers see only the summary, and a website summarising this paper already repeats its 73.5%: 41 trials (175 − 134) above the detailed count, about three in four instead of just over half.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025 · Neurology (2026) · doi:10.1212/WNL.0000000000218373